The current managements of pancreatic diabetes in Japan

Ken Kawabe, Tetsuhide Ito, Hisato Igarashi, Ryoichi Takayanagi

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Pancreatic diabetes is secondary diabetes followed by progressions of pancreatic exocrine diseases, such as chronic pancreatitis, pancreatic neoplasm and post-pancreatectomy. Because of destruction and reduction of the pancreatic endocrine and exocrine functional compartments, patients with pancreatic diabetes frequently show malnutrition from maldigestion and malabsorption by insufficiencies in pancreatic digestive enzymes, and show unstable glycemic control and prolonged hypoglycemia by insufficiencies in synthesis and secretion of insulin and glucagon. Epidemiological studies have suggested that the incidence and development of pancreatic diabetes in patients with chronic pancreatitis (CP) depends on several risk factors, such as alcohol intake, the presence of pancreatic calcification and the long-term duration of CP. The clinical management of pancreatic diabetes is divided into two parts: one is the supplementation of pancreatic digestive enzymes and the other is the achievement of appropriate glycemic control. The appropriate and sufficient pancreatic exocrine replacement therapy is important for the maintenance of better nutrient conditions for patients with pancreatic diabetes. Furthermore, the intensive insulin therapy combined with short- or ultra-short-acting insulin and long-acting insulin glargine can be achieved for stable glycemic control and reduction of severe frequent hypoglycemia in patients with pancreatic diabetes. These current advanced management techniques against insufficiencies of pancreatic exocrine endocrine functions are beneficial for improving and maintaining the quality of life in patients with pancreatic diabetes.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalClinical Journal of Gastroenterology
Volume2
Issue number1
DOIs
Publication statusPublished - Feb 1 2009

Fingerprint

Japan
Chronic Pancreatitis
Exocrine Pancreatic Insufficiency
Hypoglycemia
Long-Acting Insulin
Short-Acting Insulin
Insulin
Pancreatic Diseases
Pancreatectomy
Enzymes
Glucagon
Pancreatic Neoplasms
Malnutrition
Epidemiologic Studies
Maintenance
Alcohols
Quality of Life
Food
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

The current managements of pancreatic diabetes in Japan. / Kawabe, Ken; Ito, Tetsuhide; Igarashi, Hisato; Takayanagi, Ryoichi.

In: Clinical Journal of Gastroenterology, Vol. 2, No. 1, 01.02.2009, p. 1-8.

Research output: Contribution to journalReview article

Kawabe, Ken ; Ito, Tetsuhide ; Igarashi, Hisato ; Takayanagi, Ryoichi. / The current managements of pancreatic diabetes in Japan. In: Clinical Journal of Gastroenterology. 2009 ; Vol. 2, No. 1. pp. 1-8.
@article{185ef03ef80c4edb90879b11266c5cdf,
title = "The current managements of pancreatic diabetes in Japan",
abstract = "Pancreatic diabetes is secondary diabetes followed by progressions of pancreatic exocrine diseases, such as chronic pancreatitis, pancreatic neoplasm and post-pancreatectomy. Because of destruction and reduction of the pancreatic endocrine and exocrine functional compartments, patients with pancreatic diabetes frequently show malnutrition from maldigestion and malabsorption by insufficiencies in pancreatic digestive enzymes, and show unstable glycemic control and prolonged hypoglycemia by insufficiencies in synthesis and secretion of insulin and glucagon. Epidemiological studies have suggested that the incidence and development of pancreatic diabetes in patients with chronic pancreatitis (CP) depends on several risk factors, such as alcohol intake, the presence of pancreatic calcification and the long-term duration of CP. The clinical management of pancreatic diabetes is divided into two parts: one is the supplementation of pancreatic digestive enzymes and the other is the achievement of appropriate glycemic control. The appropriate and sufficient pancreatic exocrine replacement therapy is important for the maintenance of better nutrient conditions for patients with pancreatic diabetes. Furthermore, the intensive insulin therapy combined with short- or ultra-short-acting insulin and long-acting insulin glargine can be achieved for stable glycemic control and reduction of severe frequent hypoglycemia in patients with pancreatic diabetes. These current advanced management techniques against insufficiencies of pancreatic exocrine endocrine functions are beneficial for improving and maintaining the quality of life in patients with pancreatic diabetes.",
author = "Ken Kawabe and Tetsuhide Ito and Hisato Igarashi and Ryoichi Takayanagi",
year = "2009",
month = "2",
day = "1",
doi = "10.1007/s12328-008-0052-x",
language = "English",
volume = "2",
pages = "1--8",
journal = "Clinical Journal of Gastroenterology",
issn = "1865-7257",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - The current managements of pancreatic diabetes in Japan

AU - Kawabe, Ken

AU - Ito, Tetsuhide

AU - Igarashi, Hisato

AU - Takayanagi, Ryoichi

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Pancreatic diabetes is secondary diabetes followed by progressions of pancreatic exocrine diseases, such as chronic pancreatitis, pancreatic neoplasm and post-pancreatectomy. Because of destruction and reduction of the pancreatic endocrine and exocrine functional compartments, patients with pancreatic diabetes frequently show malnutrition from maldigestion and malabsorption by insufficiencies in pancreatic digestive enzymes, and show unstable glycemic control and prolonged hypoglycemia by insufficiencies in synthesis and secretion of insulin and glucagon. Epidemiological studies have suggested that the incidence and development of pancreatic diabetes in patients with chronic pancreatitis (CP) depends on several risk factors, such as alcohol intake, the presence of pancreatic calcification and the long-term duration of CP. The clinical management of pancreatic diabetes is divided into two parts: one is the supplementation of pancreatic digestive enzymes and the other is the achievement of appropriate glycemic control. The appropriate and sufficient pancreatic exocrine replacement therapy is important for the maintenance of better nutrient conditions for patients with pancreatic diabetes. Furthermore, the intensive insulin therapy combined with short- or ultra-short-acting insulin and long-acting insulin glargine can be achieved for stable glycemic control and reduction of severe frequent hypoglycemia in patients with pancreatic diabetes. These current advanced management techniques against insufficiencies of pancreatic exocrine endocrine functions are beneficial for improving and maintaining the quality of life in patients with pancreatic diabetes.

AB - Pancreatic diabetes is secondary diabetes followed by progressions of pancreatic exocrine diseases, such as chronic pancreatitis, pancreatic neoplasm and post-pancreatectomy. Because of destruction and reduction of the pancreatic endocrine and exocrine functional compartments, patients with pancreatic diabetes frequently show malnutrition from maldigestion and malabsorption by insufficiencies in pancreatic digestive enzymes, and show unstable glycemic control and prolonged hypoglycemia by insufficiencies in synthesis and secretion of insulin and glucagon. Epidemiological studies have suggested that the incidence and development of pancreatic diabetes in patients with chronic pancreatitis (CP) depends on several risk factors, such as alcohol intake, the presence of pancreatic calcification and the long-term duration of CP. The clinical management of pancreatic diabetes is divided into two parts: one is the supplementation of pancreatic digestive enzymes and the other is the achievement of appropriate glycemic control. The appropriate and sufficient pancreatic exocrine replacement therapy is important for the maintenance of better nutrient conditions for patients with pancreatic diabetes. Furthermore, the intensive insulin therapy combined with short- or ultra-short-acting insulin and long-acting insulin glargine can be achieved for stable glycemic control and reduction of severe frequent hypoglycemia in patients with pancreatic diabetes. These current advanced management techniques against insufficiencies of pancreatic exocrine endocrine functions are beneficial for improving and maintaining the quality of life in patients with pancreatic diabetes.

UR - http://www.scopus.com/inward/record.url?scp=77953372029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953372029&partnerID=8YFLogxK

U2 - 10.1007/s12328-008-0052-x

DO - 10.1007/s12328-008-0052-x

M3 - Review article

AN - SCOPUS:77953372029

VL - 2

SP - 1

EP - 8

JO - Clinical Journal of Gastroenterology

JF - Clinical Journal of Gastroenterology

SN - 1865-7257

IS - 1

ER -